tert-butyl 4-(6-methoxypyridin-2-yl)piperazine-1-carboxylate | 898533-41-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(6-methoxypyridin-2-yl)piperazine-1-carboxylate
• CAS: 898533-41-0
• 化学式: C₁₅H₂₃N₃O₃
• 分子量: 293.366
• InChiKey: UERPGEIDWQLDIE-UHFFFAOYSA-N

物化性质

• 沸点：
  420.9±45.0 °C(Predicted)
• 密度：
  1.140±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  54.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(6-methoxypyridin-2-yl)piperazine-1-carboxylate 在 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 13.0h， 生成 N-(4-(4-(6-methoxypyridin-2-yl)piperazin-1-yl)butyl)benzamide
  参考文献：
  名称：

  Targeting Dopamine D₃ and Serotonin 5-HT_1A and 5-HT_2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies

  摘要：

  Combination of dopamine D-3 antagonism, serotonin 5-HT1A partial agonism, and antagonism at 5-HT2A leads to a novel approach to potent atypical antipsychotics. Exploitation of the original structureactivity relationships resulted in the identification of safe and effective antipsychotics devoid of extrapyramidal symptoms liability, sedation, and catalepsy. The potential atypical antipsychotic 5bb was selected for further pharmacological investigation. The distribution of c-fos positive cells in the ventral striatum confirmed the atypical antipsychotic profile of 5bb in agreement with behavioral rodent studies. 5bb administered orally demonstrated a biphasic effect on the MK801-induced hyperactivity at dose levels not able to induce sedation, catalepsy, or learning impairment in passive avoidance. In microdialysis studies, 5bb increased the dopamine efflux in the medial prefrontal cortex. Thus, 5bb represents a valuable lead for the development of atypical antipsychotics endowed with a unique pharmacological profile for addressing negative symptoms and cognitive deficits in schizophrenia.

  DOI：

  10.1021/jm501119j
• 作为产物：
  描述：

  2-溴-6-甲氧基吡啶 、 N-Boc-哌嗪 在 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 1.5h， 以75%的产率得到tert-butyl 4-(6-methoxypyridin-2-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  Targeting Dopamine D₃ and Serotonin 5-HT_1A and 5-HT_2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies

  摘要：

  Combination of dopamine D-3 antagonism, serotonin 5-HT1A partial agonism, and antagonism at 5-HT2A leads to a novel approach to potent atypical antipsychotics. Exploitation of the original structureactivity relationships resulted in the identification of safe and effective antipsychotics devoid of extrapyramidal symptoms liability, sedation, and catalepsy. The potential atypical antipsychotic 5bb was selected for further pharmacological investigation. The distribution of c-fos positive cells in the ventral striatum confirmed the atypical antipsychotic profile of 5bb in agreement with behavioral rodent studies. 5bb administered orally demonstrated a biphasic effect on the MK801-induced hyperactivity at dose levels not able to induce sedation, catalepsy, or learning impairment in passive avoidance. In microdialysis studies, 5bb increased the dopamine efflux in the medial prefrontal cortex. Thus, 5bb represents a valuable lead for the development of atypical antipsychotics endowed with a unique pharmacological profile for addressing negative symptoms and cognitive deficits in schizophrenia.

  DOI：

  10.1021/jm501119j

文献信息

• Novel Aryl Piperazine Derivatives With Medical Utility
  申请人：Campiani Giuseppe

  公开号：US20090238761A1

  公开（公告）日：2009-09-24

  This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D 3 , D 2 -like and 5-HT 2 receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders incl. schizophrenia.

  这项发明提供了具有医疗效用的新型芳基哌嗪衍生物，特别是作为多巴胺和5-羟色胺受体的调节剂，优选为D3、D2样和5-HT2受体亚型，特别适用于治疗包括精神分裂症在内的神经精神障碍。
• Electrochemically Driven, Ni-Catalyzed Aryl Amination: Scope, Mechanism, and Applications
  作者：Yu Kawamata、Julien C. Vantourout、David P. Hickey、Peng Bai、Longrui Chen、Qinglong Hou、Wenhua Qiao、Koushik Barman、Martin A. Edwards、Alberto F. Garrido-Castro、Justine N. deGruyter、Hugh Nakamura、Kyle Knouse、Chuanguang Qin、Khalyd J. Clay、Denghui Bao、Chao Li、Jeremy T. Starr、Carmen Garcia-Irizarry、Neal Sach、Henry S. White、Matthew Neurock、Shelley D. Minteer、Phil S. Baran

  DOI：10.1021/jacs.9b01886

  日期：2019.4.17

  C-N cross-coupling is one of the most valuable and widespread transformations in organic synthesis. Largely dominated by Pd- and Cu-based catalytic systems, it has proven to be a staple transformation for those in both academia and industry. The current study presents the development and mechanistic understanding of an electrochemically driven, Ni-catalyzed method for achieving this reaction of high

  CN 交叉偶联是有机合成中最有价值和最广泛的转化之一。它主要由 Pd 和 Cu 基催化系统主导，已被证明是学术界和工业界人士的主要转变。目前的研究展示了一种电化学驱动的镍催化方法的发展和机理理解，以实现这种具有高度战略重要性的反应。通过一系列电化学、计算、动力学和经验实验，该反应的关键机制特征已被揭开，从而产生了适用于广泛芳基卤化物和胺亲核试剂的第二代条件，包括复杂的例子寡肽、药用杂环、天然产物和糖。
• [EN] CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS<br/>[FR] CYANOCYCLOPROPYLCARBOXAMIDES EN TANT QU'INHIBITEURS DE CATHEPSINE
  申请人：ASTRAZENECA AB

  公开号：WO2009001127A1

  公开（公告）日：2008-12-31

  [EN] The present invention relates to compounds of formula (I) for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.
  [FR] L'invention concerne des composés de formule (I) destinés au traitement de maladies associées à l'activité de la cystéine protéase. Les composés selon l'invention sont des inhibiteurs réversibles de cystéines protéases, notamment des cathepsines B, K, C, F, H, L, O, S, W et X. Les maladies associées à la cathepsine K font l'objet d'un intérêt particulier.